Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival (Q34257135)

31 July 2017

title

Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival (English)

1 reference

31 July 2017

Cristina Boschini

7

0 references

Angela Gueli

Angela Gueli

2

0 references

Giuseppe Gritti

Giuseppe Gritti

6

0 references

Marco Ruella

Marco Ruella

10

0 references

Alessandro Rambaldi

13

Alessandro Rambaldi

1 reference

31 July 2017

Corrado Tarella

1

1 reference

31 July 2017

Federica Delaini

3

1 reference

31 July 2017

Andrea Rossi

4

1 reference

31 July 2017

Anna Maria Barbui

5

1 reference

31 July 2017

Daniele Caracciolo

8

1 reference

31 July 2017

Riccardo Bruna

9

1 reference

31 July 2017

Daniela Gottardi

11

1 reference

31 July 2017

Roberto Passera

12

1 reference

31 July 2017

language of work or name

English

0 references

publication date

25 September 2014

1 reference

31 July 2017

1 reference

31 July 2017

volume

9

1 reference

31 July 2017

issue

9

1 reference

31 July 2017

page(s)

e106745

1 reference

Creative Commons Attribution 4.0 International

31 July 2017

copyright license

start time

25 September 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

Management of indolent lymphoma: where are we now and where are we going

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

The aggressive peripheral T‐cell lymphomas: 2012 update on diagnosis, risk stratification, and management

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

Diffuse large B Cell lymphoma: How can we cure more patients in 2012?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

MYC diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

Non-Hodgkin's lymphoma: the old and the new.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

The complex landscape of genetic alterations in mantle cell lymphoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

New therapeutic targets and drugs in non-Hodgkinʼs lymphoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

Novel Therapeutics for Aggressive Non-Hodgkin's Lymphoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

Double-hit B-cell lymphomas

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

Highly aggressive lymphomas in adults

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

Statistical aspects of the analysis of data from retrospective studies of disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study.

6 July 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0106745

A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0106745

Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0106745

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0106745

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0106745

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0106745

SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0106745

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0106745

The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0106745

Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0106745

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0106745

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0106745

Allogeneic transplantation following nonmyeloablative conditioning for aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0106745

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0106745

Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177839

Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

28 October 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0106745

Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25255081

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Setting the stage for biosimilar monoclonal antibodies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25255081

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PONE.0106745

1 reference

release_rmp26tofljhtrfpqdln73z4a54

31 July 2017

0 references

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rmp26tofljhtrfpqdln73z4a54

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMC publication ID

4177839

1 reference

31 July 2017

1 reference